January 2026 Town Hall
In our January Town Hall, we partnered with Paradigm Therapeutics for an engaging and educational discussion on their journey to develop a whole body topical therapy for patients across all subtypes of EB. Zorblisa (SD-101) is a proprietary new molecular entity (NME) that has a multifaceted pharmacological action on the skin, wound environment and wound healing process, including promoting the formation of epithelial and granulation tissue and removal of necrotic tissue, as well as keratolytic and anti-inflammatory effects.
Our speaker:
Dr. Robert Ryan
Dr. Robert Ryan is currently the CEO of Paradigm Therapeutics, a biotech based in South Carolina focused on the development of a whole skin surface topical therapy for the treatment of Epidermolysis Bullosa. In addition, Dr. Ryan is also the Co-Founder and CEO of Innova Therapeutics, focused on the treatment of various cancers. Dr. Ryan was previously CEO and co-founder of Scioderm, which is a company that developed a topical therapy for a rare genetic disease, namely Epidermolysis Bullosa. Scioderm was the first Biotech to receive “Breakthrough Therapy” designation from the FDA and was also recognized by Fierce Biotech as one of the Fierce 15, considered as one of the most promising Biotechs in the world. Dr. Ryan has more than 35 years of research, pharmaceutical, and biotech experience, spanning the global development process from preclinical through Phase IV.
Our speaker:
Dr. Robert Ryan
Dr. Robert Ryan is currently the CEO of Paradigm Therapeutics, a biotech based in South Carolina focused on the development of a whole skin surface topical therapy for the treatment of Epidermolysis Bullosa. In addition, Dr. Ryan is also the Co-Founder and CEO of Innova Therapeutics, focused on the treatment of various cancers. Dr. Ryan was previously CEO and co-founder of Scioderm, which is a company that developed a topical therapy for a rare genetic disease, namely Epidermolysis Bullosa. Scioderm was the first Biotech to receive “Breakthrough Therapy” designation from the FDA and was also recognized by Fierce Biotech as one of the Fierce 15, considered as one of the most promising Biotechs in the world. Dr. Ryan has more than 35 years of research, pharmaceutical, and biotech experience, spanning the global development process from preclinical through Phase IV.
January Town Hall Summary
In January’s Town Hall, we began with a brief update on EBRP and our recent progress. Allison, EBRP’s Director of Programs, then introduced Dr. Robert Ryan, who shared background on Paradigm Therapeutics and its mission. Dr. Ryan provided an overview of SD-101, which is being developed as a whole-body treatment for all EB subtypes.
Dr. Ryan then reviewed a summary of the SD-101 clinical trial results, discussed the upcoming Phase 3 trial, and outlined overall goals for 2026 and beyond.
Following Dr. Ryan’s presentation, we held an interactive Q&A session where he answered both pre-submitted questions and live questions from the audience.
Dr. Ryan then reviewed a summary of the SD-101 clinical trial results, discussed the upcoming Phase 3 trial, and outlined overall goals for 2026 and beyond.
Following Dr. Ryan’s presentation, we held an interactive Q&A session where he answered both pre-submitted questions and live questions from the audience.
EBRP live Town Halls
Our monthly Live Town Halls help drive research and awareness with informative discussions led by trusted specialists and advocates in the EB space. Topics include current research, clinical trials, caring for loved ones with EB, and more. Town Halls are open to anyone interested in learning more about EB and the future of EB treatment and care. Check out more of our Town Halls here.
To register for our next Live Town Hall, click here.
To register for our next Live Town Hall, click here.
